Dr Xinhong Lim is a Venture Partner. He joined Vickers Venture Partners in 2015 and left the full-time position in 2023. While at Vickers, he led investments into companies in the life sciences, medical device, AI and advanced materials sectors, and advises on fund strategy in these areas. Xinhong serves as a director on the boards of RWDC (sustainable biopolymers) and Emergex (synthetic T-cell vaccines), and as an observer on the boards of Aardvark (metabolic and inflammatory disease therapeutics), Lumitron (extremely brilliant X-ray compact light sources), Sisaf (silicon-stabilized lipid nanoparticles for RNA delivery) and Biosplice (RNA-splicing modulatory therapeutics). He is concurrently serving as Chief Strategy Officer and a member of the Executive Committee of RWDC. 

Xinhong received his Ph.D. in Developmental Biology from Stanford University under the tutelage of Breakthrough Prize winner Professor Roel Nusse, and obtained a Certificate in Innovation and Entrepreneurship from the Stanford Graduate School of Business. He received a B.S. in Biochemistry from the University of Wisconsin-Madison, where he graduated with Highest Distinction. Xinhong is an Assistant Professor (Adjunct) at the Skin Research Institute of Singapore (SRIS) and NTU LKC School of Medicine. He has served as an invited speaker for many international professional and scientific conferences and has been the principal investigator for more than $15 million of research grants. Xinhong’s work has been published and cited in the most prestigious scientific journals, including Nature and Science, as well as highlighted in the international press, including by CNN and BBC. He is the recipient of numerous awards, including the Singapore National Academy of Sciences Young Scientist Award and the Ten Outstanding Young Singaporeans Award (Medical Innovation). Xinhong is fluent in English, Mandarin and Cantonese, and has a working knowledge of French.